ArticleMolecular cancer research : MCR2020
Open access · bronzeAbstract read
In one paragraph
Article in Molecular cancer research : MCR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.1field-weighted citation impact, top 19% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 52 citations in OpenAlex.
- Experimental Models and Nanotechnology-Based Platforms in Oral Squamous Cell Carcinoma: From Tumor Biology to Translational Applications.Pharmaceutics · 2026Review
- A new functional assay reveals that membrane binding is critical for overactivation of the phosphoinositide 3-kinase H1047R mutant.The Journal of biological chemistry · 2026Article
- Studies Combining Network Pharmacology withCombinatorial chemistry & high throughput screening · 2026Article
- Review
- Anti-PD1 prolongs the response of PI3K and farnesyl transferase inhibition in HRAS- and PIK3CA-mutant head and neck cancers.Neoplasia (New York, N.Y.) · 2025Article
- Squamous cell cancers of the aero-upper digestive tract: A unified perspective on biology, genetics, and therapy.Cancer cell · 2025Review
- Connecting the dots: investigating the link between environmental, genetic, and epigenetic influences in metabolomic alterations in oral squamous cell carcinoma.Journal of experimental & clinical cancer research : CR · 2024Review
- Article
- Understanding PI3K/Akt/mTOR signaling in squamous cell carcinoma: mutated PIK3CA as an example.Molecular biomedicine · 2024Review
- Genes involved in metastasis in oral squamous cell carcinoma: A systematic review.Health science reports · 2024Article
- A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation.Molecular cancer · 2024Article
- Towards system genetics analysis of head and neck squamous cell carcinoma using the mouse model, cellular platform, and clinical human data.Animal models and experimental medicine · 2023Review
- Physapruin A Enhances DNA Damage and Inhibits DNA Repair to Suppress Oral Cancer Cell Proliferation.International journal of molecular sciences · 2022Article
- Differential responses to immune checkpoint inhibitor dictated by pre-existing differential immune profiles in squamous cell carcinomas caused by same initial oncogenic drivers.Journal of experimental & clinical cancer research : CR · 2022Article
- Why responses to immune checkpoint inhibitors are heterogeneous in head and neck cancers: Contributions from tumor-intrinsic and host-intrinsic factors.Frontiers in oncology · 2022Review
- Article
- Dendrobine suppresses endoplasmic reticulum stress-induced apoptosis through upregulating microRNA miR-381-3p to decrease caspase-4.Bioengineered · 2021Article
- Stromal cells in the tumor microenvironment promote the progression of oral squamous cell carcinoma.International journal of oncology · 2021Article
- A Claudin-Based Molecular Signature Identifies High-Risk, Chemoresistant Colorectal Cancer Patients.Cells · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 2 countries.
Darío García-CarracedoHerbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York.
Yi CaiDepartment of Otolaryngology - Head and Neck Surgery, Columbia University Irving Medical Center, New York, New York.
Wanglong QiuHerbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York.
Kiyoshi SaekiHerbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York.
Richard A FriedmanHerbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York.
Andrew LeeDepartment of Otolaryngology - Head and Neck Surgery, Columbia University Irving Medical Center, New York, New York.ORCID 0000-0003-4224-978X
Yinglu LiDepartment of Genetics and Development, Columbia University Medical Center, New York, New York.
Elizabeth M GoldbergDepartment of Genetics and Development, Columbia University Medical Center, New York, New York.ORCID 0000-0002-4943-506X
Elias E StratikopoulosDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
Ramon ParsonsDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
Chao LuDepartment of Genetics and Development, Columbia University Medical Center, New York, New York.
Argiris EfstratiadisBiomedical Research Foundation, Academy of Athens, Athens, Greece.
Elizabeth M PhiliponeDivision of Oral and Maxillofacial Pathology, Columbia University College of Dental Medicine, New York, New York.
Angela J YoonDivision of Oral and Maxillofacial Pathology, Columbia University College of Dental Medicine, New York, New York.
Gloria H SuHerbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York. gs2157@columbia.edu.
Columbia University Irving Medical Center · USColumbia University · USIcahn School of Medicine at Mount Sinai · USAcademy of Athens · GR
Funding
PTEN and CancerR35CA220491 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI PARSONS, RAMON E · 2017 to 2023
$6.8MMouse Model for Human Pancreatic Ductal AdenocarcinomaR01CA109525 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SU, GLORIA HUEI-TING · 2004 to 2015
$2.6MThe Development And Progression Of IPMN To PDA In The Context Of Inactivated Activin SignalingR01CA217207 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SU, GLORIA HUEI-TING · 2017 to 2021
$2.4MNSD1 Inactivation in Head and Neck CancerR00CA212257 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI LU, CHAO · 2018 to 2020
$686kMouse Model for Human Pancreatic Ductal AdenocarcinomaR56CA109525 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SU, GLORIA HUEI-TING · 2009 to 2009
$251kNCI NIH HHS R00 CA212257NCI NIH HHS R01 CA109525NCI NIH HHS R01 CA217207NCI NIH HHS R35 CA220491NCI NIH HHS R56 CA109525
Abstract
The PI3K signaling pathway is frequently mutated in head and neck squamous cell carcinoma (HNSCC), often via gain-of-function (GOF) mutations in the
Indexed as
Mutation4-Nitroquinoline-1-oxideAnimalsCarcinogensClass I Phosphatidylinositol 3-KinasesDisease ProgressionHead and Neck NeoplasmsMiceMice, NudeSquamous Cell Carcinoma of Head and NeckTumor Suppressor Protein p534-Nitroquinoline-1-oxideCarcinogensClass I Phosphatidylinositol 3-KinasesPik3ca protein, mouseTrp53 protein, mouseTumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.